Tenderwize
Zurück zur Suche

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 186 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Certolizumab pegol , ATC L04AB05

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for Certolizumab pegol (ATC L04AB05) under the open-house model.
  • Contracts have uniform terms and conditions, no individual negotiations.
Vollständige Zusammenfassung anzeigen

Non-exclusive discount agreement (open-house model) for the active substance Certolizumab pegol (ATC L04AB05), offered by AOK Rheinland-Pfalz/Saarland. All interested pharmaceutical companies meeting eligibility may join at uniform terms. Contracts run max 24 months (earliest start 01.05.2025, ending 30.04.2027). The buyer may replace with exclusive contracts during the term. First submission deadline: 31.03.2025; subsequent monthly deadlines. Notice is a voluntary transparency publication, not a formal EU procurement.

Risiken

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Evidence of marketability via Lauer-Taxe listing or AMIce database extract required.

Eligibility

  • Only pharmaceutical products authorized and marketable in Germany are eligible.

Administrative

  • Submission of signed contract documents and required evidence by the specified deadlines.

Zuschlagskriterien

Lot 1

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Auftraggeber

Lose (1)

LOT-0001

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

Non-exclusive discount contracts for the supply of pharmaceutical products containing the active substance Certolizumab pegol (ATC L04AB05) to the AOK Rheinland-Pfalz/Saarland. All qualified pharmaceutical companies can join on standard terms. Duration: up to 24 months from 01.05.2025 to 30.04.2027. Rolling entry possible monthly. Uniform conditions, no negotiations. Subject to early termination if buyer awards exclusive contracts.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
12 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
164685-2025

Dokumente (1)

Ähnliche Ausschreibungen